These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 23662021)
1. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. Chawla S; Kaushik N; Singh NP; Ghosh RK; Saxena A J Pharmacol Pharmacother; 2013 Jan; 4(1):27-32. PubMed ID: 23662021 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P; Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [TBL] [Abstract][Full Text] [Related]
3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P; Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112 [TBL] [Abstract][Full Text] [Related]
5. Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin. Jameshorani M; Sayari S; Kiahashemi N; Motamed N Open Access Maced J Med Sci; 2017 Dec; 5(7):955-962. PubMed ID: 29362626 [TBL] [Abstract][Full Text] [Related]
6. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Srivastava S; Saxena GN; Keshwani P; Gupta R J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111 [TBL] [Abstract][Full Text] [Related]
7. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial. Peng XV; Marcinak JF; Raanan MG; Cao C Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726 [TBL] [Abstract][Full Text] [Related]
9. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706 [TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458 [TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. Devarajan TV; Venkataraman S; Kandasamy N; Oomman A; Boorugu HK; Karuppiah SKP; Balat D Indian J Endocrinol Metab; 2017; 21(5):745-750. PubMed ID: 28989886 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P; J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760 [TBL] [Abstract][Full Text] [Related]
15. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Umpierrez G; Issa M; Vlajnic A Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436 [TBL] [Abstract][Full Text] [Related]
16. Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial. Zhang F; Tang L; Li J; Yan Z; Li J; Tong N Diabetes Metab Syndr Obes; 2021; 14():1243-1252. PubMed ID: 33776461 [TBL] [Abstract][Full Text] [Related]
17. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744 [TBL] [Abstract][Full Text] [Related]
18. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC; Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415 [TBL] [Abstract][Full Text] [Related]
19. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594 [TBL] [Abstract][Full Text] [Related]
20. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W; Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]